

# Letizia Porcelli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7264891/publications.pdf>

Version: 2024-02-01

69  
papers

1,685  
citations

279798

23  
h-index

302126

39  
g-index

72  
all docs

72  
docs citations

72  
times ranked

3574  
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells. <i>Scientific Reports</i> , 2019, 9, 4099.	3.3	112
2	Cyclohexylpiperazine derivative PB28, a $\beta$ 2 agonist and $\beta$ 1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1807-1816.	4.1	108
3	Hepatic stellate cells induce hepatocellular carcinoma cell resistance to sorafenib through the laminin $\alpha$ 3 $\beta$ 3 integrin axis recovery of focal adhesion kinase ubiquitination. <i>Hepatology</i> , 2016, 64, 2103-2117.	7.3	80
4	Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 362-373.	3.0	78
5	CAFs and TGF- $\beta$ 2 Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer. <i>Cancers</i> , 2019, 11, 330.	3.7	71
6	Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study. <i>Cancers</i> , 2019, 11, 942.	3.7	66
7	Targeting human liver cancer cells with lactobionic acid-G(4)-PAMAM-FITC sorafenib loaded dendrimers. <i>International Journal of Pharmaceutics</i> , 2017, 528, 485-497.	5.2	57
8	Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma. <i>Molecular Cancer</i> , 2022, 21, 20.	19.2	55
9	The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa $\text{\textsuperscript{\textcircled{R}}}$ , ZD1839). <i>Biochemical Pharmacology</i> , 2004, 68, 135-144.	4.4	54
10	Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. <i>Molecular Oncology</i> , 2013, 7, 308-322.	4.6	54
11	Sorafenib delivery nanoplatform based on superparamagnetic iron oxide nanoparticles magnetically targets hepatocellular carcinoma. <i>Nano Research</i> , 2017, 10, 2431-2448.	10.4	54
12	Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer. <i>British Journal of Cancer</i> , 2011, 104, 769-780.	6.4	52
13	Laminin-5 offsets the efficacy of gefitinib ( $\text{\textsuperscript{\textcircled{R}}}$ Iressa $\text{\textsuperscript{\textcircled{R}}}$ ) in hepatocellular carcinoma cells. <i>British Journal of Cancer</i> , 2004, 91, 1964-1969.	6.4	50
14	EGFR and VEGFR as potential target for biological therapies in HCC cells. <i>Cancer Letters</i> , 2008, 262, 257-264.	7.2	48
15	Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells. <i>Biochemical Pharmacology</i> , 2008, 75, 1035-1044.	4.4	47
16	Synthesis, Characterization and Biological Evaluation of Ureidofibrate-Like Derivatives Endowed with Peroxisome Proliferator-Activated Receptor Activity. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 37-54.	6.4	46
17	Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 335-346.	2.3	45
18	EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 1962.	3.0	42

#	ARTICLE	IF	CITATIONS
19	ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells. <i>Biochemical Pharmacology</i> , 2006, 71, 479-485.	4.4	36
20	Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy. <i>Journal of Translational Medicine</i> , 2015, 13, 26.	4.4	34
21	New insight into the role of metabolic reprogramming in melanoma cells harboring BRAF mutations. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 2710-2718.	4.1	27
22	Intracellular Trafficking of MDR Transporters and Relevance of SNPs. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 197-208.	2.1	25
23	Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa®, <sup>®</sup> ) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects. <i>World Journal of Gastroenterology</i> , 2006, 12, 5140.	3.3	25
24	uPAR <sup>+</sup> extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients. , 2021, 9, e002372.		23
25	The EGFR Pathway Regulates BCRP Expression in NSCLC Cells: Role of Erlotinib. <i>Current Drug Targets</i> , 2014, 15, 1322-1330.	2.1	23
26	Microfluidic preparation and in vitro evaluation of iRGD-functionalized solid lipid nanoparticles for targeted delivery of paclitaxel to tumor cells. <i>International Journal of Pharmaceutics</i> , 2021, 610, 121246.	5.2	23
27	Irradiation-induced angiosarcoma and anti-angiogenic therapy: A therapeutic hope?. <i>Experimental Cell Research</i> , 2014, 321, 240-247.	2.6	21
28	The Impact of Folate Status on the Efficacy of Colorectal Cancer Treatment. <i>Current Drug Metabolism</i> , 2011, 12, 975-984.	1.2	19
29	Synthesis, Characterization, and Cytotoxicity of the First Oxaliplatin Pt(IV) Derivative Having a TSPO Ligand in the Axial Position. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1010.	4.1	19
30	Synthetic Lethality to Overcome Cancer Drug Resistance. <i>Current Medicinal Chemistry</i> , 2012, 19, 3858-3873.	2.4	18
31	Tomatine Displays Antitumor Potential in In Vitro Models of Metastatic Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5243.	4.1	18
32	The $\beta$ -adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study. <i>Scientific Reports</i> , 2020, 10, 10465.	3.3	18
33	The Coordinated Role of CYP450 Enzymes and P-gp in Determining Cancer Resistance to Chemotherapy. <i>Current Drug Metabolism</i> , 2011, 12, 713-721.	1.2	17
34	Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer. <i>Cell Death and Disease</i> , 2014, 5, e1076-e1076.	6.3	17
35	The Role of Non-Coding RNAs as Prognostic Factor, Predictor of Drug Response or Resistance and Pharmacological Targets, in the Cutaneous Squamous Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2552.	3.7	16
36	Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 111006.	5.6	16

#	ARTICLE	IF	CITATIONS
37	Behind the Scene: Exploiting MC1R in Skin Cancer Risk and Prevention. <i>Genes</i> , 2021, 12, 1093.	2.4	15
38	p53 as the main traffic controller of the cell signaling network. <i>Frontiers in Bioscience - Landmark</i> , 2010, 15, 1172.	3.0	12
39	Microfluidic-Assisted Preparation of Targeted pH-Responsive Polymeric Micelles Improves Gemcitabine Effectiveness in PDAC: In Vitro Insights. <i>Cancers</i> , 2022, 14, 5.	3.7	12
40	MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment. <i>European Journal of Pharmacology</i> , 2011, 670, 74-84.	3.5	10
41	The ER $\alpha$ -VDR axis promotes calcitriol degradation and estrogen signaling in breast cancer cells, while VDR $\alpha$ -CYP24A1 $\alpha$ overexpression correlates with poor prognosis in patients with basal-like breast cancer. <i>Molecular Oncology</i> , 2022, 16, 904-920.	4.6	10
42	Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors. <i>Current Pharmaceutical Design</i> , 2013, 19, 918-926.	1.9	9
43	Metastatic melanoma cells with BRAF G469A mutation: nab-paclitaxel better than vemurafenib?. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 433-438.	2.3	9
44	Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4681-4686.	2.0	9
45	The Interaction between Reactive Peritoneal Mesothelial Cells and Tumor Cells via Extracellular Vesicles Facilitates Colorectal Cancer Dissemination. <i>Cancers</i> , 2021, 13, 2505.	3.7	9
46	Grape seed extracts modify the outcome of oxaliplatin in colon cancer cells by interfering with cellular mechanisms of drug cytotoxicity. <i>Oncotarget</i> , 2017, 8, 50845-50863.	1.8	9
47	Detrimental effects of melanocortin-1 receptor (MC1R) variants on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 679-687.	3.3	8
48	Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 6287.	3.3	8
49	BRAFV600E;K601Q metastatic melanoma patient-derived organoids and docking analysis to predict the response to targeted therapy. <i>Pharmacological Research</i> , 2022, 182, 106323.	7.1	8
50	Synthesis and biological evaluation of N-biphenyl-nicotinic based moiety compounds: A new class of antimitotic agents for the treatment of Hodgkin Lymphoma. <i>Cancer Letters</i> , 2019, 445, 1-10.	7.2	7
51	Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function. <i>Journal of Cellular Physiology</i> , 2020, 235, 8085-8097.	4.1	7
52	New Vascular Disrupting Agents in Upper Gastrointestinal Malignancies. <i>Current Medicinal Chemistry</i> , 2014, 21, 1039-1049.	2.4	7
53	Nti-EGFR monoclonal antibody in cancer treatment: in vitro and in vivo evidence. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 1973.	3.0	7
54	Probing the interaction between cisplatin and the therapeutic monoclonal antibody trastuzumab. <i>RSC Advances</i> , 2016, 6, 29229-29236.	3.6	4

#	ARTICLE	IF	CITATIONS
55	Hydroxy-Propil-β-Cyclodextrin Inclusion Complexes of two Biphenylnicotinamide Derivatives: Formulation and Anti-Proliferative Activity Evaluation in Pancreatic Cancer Cell Models. International Journal of Molecular Sciences, 2020, 21, 6545.	4.1	4
56	Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells. International Journal of Molecular Medicine, 2008, 21, 809-17.	4.0	3
57	Long Non-Coding RNA Landscape in Prostate Cancer Molecular Subtypes: A Feature Selection Approach. International Journal of Molecular Sciences, 2021, 22, 2227.	4.1	2
58	275 SORAFENIB EFFECTIVENESS IS INHIBITED IN PRESENCE OF LAMININ-5 IN HCC CELLS. Journal of Hepatology, 2012, 56, S114.	3.7	1
59	Possible role of vascular endothelial growth factor (VEGF) levels in immunodepleted plasma of metastatic colorectal cancer (mCRC) patients (pts) treated with a biweekly administration of capecitabine plus oxaliplatin (XELOX-2) plus bevacizumab: Preliminary results.. Journal of Clinical Oncology, 2011, 29, e14155-e14155.	1.6	1
60	257 An inhibitor of VEGF(ZD6474) as a potential new drug for HCC: A preclinical study. Journal of Hepatology, 2006, 44, S102.	3.7	0
61	34 AZD1152 PLUS GEMCITABINE FOR PANCREAS CANCER TREATMENT: IN VITRO AND IN VIVO STUDY. Cancer Treatment Reviews, 2010, 36, S105.	7.7	0
62	46 IS BCRP EXPRESSION AND LOCALIZATION REGULATED BY EGFR PATHWAY IN NSCLC CELLS?. Cancer Treatment Reviews, 2010, 36, S108.	7.7	0
63	47 BIOLOGICAL CHARACTERIZATION OF MC70, AS POTENT INHIBITOR OF ABC TRANSPORTERS INVOLVED IN MULTIDRUG RESISTANCE. Cancer Treatment Reviews, 2010, 36, S109.	7.7	0
64	844: A novel strategy for the treatment of Hodgkin lymphoma. European Journal of Cancer, 2014, 50, S205.	2.8	0
65	P74 LAMININ-5 INDUCES RESISTANCE TO SORAFENIB IN HCC PRECLINICAL MODELS. Journal of Hepatology, 2014, 60, S91.	3.7	0
66	Mast Cells (MCs) Infiltration Affects Pancreatic Cancer (PC) Response To Gemcitabine Based Chemotherapy: In Vitro New Insights. Annals of Oncology, 2015, 26, vi101.	1.2	0
67	Possible predictive role of the soluble cd40 ligand (scd40l) in metastatic pancreatic ductal adenocarcinoma (PDAC) patients (pts) treated with first line folfirinox or gemcitabine/nab-paclitaxel combination. Annals of Oncology, 2015, 26, vi99.	1.2	0
68	Potential therapeutic combination of beta-blockers and trabectedin in metastatic soft tissue sarcoma and ovarian cancer. Annals of Oncology, 2017, 28, vi66-vi67.	1.2	0
69	Abstract 2238: Synergistic effect of sunitinib and PD-1 inhibitor nivolumab on colorectal cancer in vitro and in vivo. , 2020, , .		0